Skip to main content
Premium Trial:

Request an Annual Quote

J&J Pharma R&D Signs On for Five More Years with Entelos

NEW YORK, March 16 (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will collaborate with Entelos to research multiple therapeutic areas for five more years, Entelos said today.


Under the agreement, Entelos engineers and scientists will use the PhysioLab platforms to "support specific projects ... on behalf of J&JPRD and its affiliates," the company said in a statement.


Financial details were not provided.


As GenomeWeb News reported last week, Entelos is unalarmed about the recent downsizing at J&JPRD. The two companies also recently expanded a hemotology research collaboration.


"We believe J&JPRD's continued commitment to apply the power of biosimulation to the drug discovery and development decisions will lead to safer and more effective medicines for patients," Entelos president and CEO James Karis said in a statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.